AstraZeneca: Capivasertib in Combination With Faslodex Granted Priority Review in the US for Patients With Advanced HR-Positive Breast Cancer
June 13, 2023
June 13, 2023
WILMINGTON, Delaware, June 13 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
AstraZeneca's New Drug Application (NDA) for capivasertib in combination with FASLODEX(R) (fulvestrant) has been accepted and granted Priority Review in the US for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer following recurrence or prog . . .
AstraZeneca's New Drug Application (NDA) for capivasertib in combination with FASLODEX(R) (fulvestrant) has been accepted and granted Priority Review in the US for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer following recurrence or prog . . .